Objective: To explore water soluble metabolite features of brain tumor specimens with HRMAS-1HMRS and its potential clinical value. Methods: There were thirty cases of pathologically proven brain tumor, including 6 I-II grade astrocy- tomas, 7 III grade anaplastic astrocytomas, 10 IV grade glioblastomas and 7 meningiomas. Used Varian Company 600 MHz spectrometer with the Nano-probe for acquisition HRMAS-1HMRS, which was postprocessed with jMRUI 3.2 version software. These metabolic probability and their ratios to Cr were summed. Results: (1) HRMAS-1HMRS could resolve NAA, PCr/Cr, GPC + PCho + Cho, Glu/Gln, Gly, Tau, Ala, Lac, mI and so on. All samples showed Lac, 6 samples showed unknown single peak at 3.72 ppm or 3.90 ppm. (2) The mean Cho/Cr of 6 I-II grade astrocytomas was 2.42 ± 1.01 (P = 0.003, compared with glioblastoma). The mean Cho/Cr of 7 anaplastic astrocytomas was 3.48 ± 0.59 (P = 0.01, compared with glioblastoma). The Cho/Cr of 10 glioblastomas broadly ranged from 0.9 to 11.3 (mean 5.40 ± 1.23). From I-II grade astrocytoma to glioblastoma, Ala/Cr, Tau/Cr and Gly/Cr trends were increased; the mean Ala/Cr of glioma was 0.31 ± 0.13. (3) Meningiomas showed higher Ala and Cho. Their Cr was lower than that of gliomas. 4/7 cases had no NAA, 3/7 patients had lower NAA. Mean Cho/Cr was 3.56 ± 1.01, Ala/Cr was 0.53 ± 0.28 (P = 0.006, compared with glioma). Conclusion: HRMAS-1HMRS can show further details in vivo MRS, resolve in vivo spectroscopic metabolite of Cho compound and differentiate the extent of benign and ma- lignant glioma. With the increase in the malignant degree of gliomas, Cho, mI, Ala, Tau and Gly will increase. HRMAS-1HMRS is the only method of isotropic spectroscopy for pathological specimens. Objective: To explore water soluble metabolite features of brain tumor specimens with HRMAS-1HMRS and its potential clinical value. Methods: There were thirty cases of pathologically proven brain tumor, including 6 I-II grade astrocy- tomas, 7 III grade anaplastic astrocytomas, 10 IV grade glioblastomas and 7 meningiomas. Used Varian Company 600 MHz spectrometer with the Nano-probe for acquisition HRMAS-1HMRS, which was postprocessed with jMRUI 3.2 version software. These metabolic probability and their ratios to Cr were summed. Results: (1) HRMAS-1HMRS could resolve NAA, PCr / Cr, GPC + PCho + Cho, Glu / Gln, Gly, Tau, Ala, Lac, mI and so on. All samples showed Lac, 6 samples showed unknown single peak at 3.72 ppm or 3.90 (2) The mean Cho / Cr of 6 I-II grade astrocytomas was 2.42 ± 1.01 (P = 0.003, compared with glioblastoma). The mean Cho / Cr of 7 anaplastic astrocytomas was 3.48 ± 0.59 with glioblastoma. The Cho / Cr of 10 glioblastomas broadly ranged from 0.9 to 11.3 (mean 5.40 ± 1.23). From I-II grade astrocytoma to glioblastoma, Ala / Cr, Tau / Cr and Gly / Cr trends were increased; the mean Ala / Cr of glioma was 0.31 ± 0.13. Mean Cho / Cr was 3.56 ± 1.01, Ala / Cr was 0.53 ± 0.28 (P = 0.006, compared with glioma). Conclusion: HRMAS-1HMRS can show further details in vivo MRS, resolve in vivo spectroscopic metabolite of Cho compound and differentiate the extent of benign and maignitant glioma. With the increase in the malignant degree of gliomas, Cho, mI, Ala, Tau and Gly will increase. HRMAS-1HMRS is the only method of isotropic spectroscopy for pathological specimens.